Log in
Sign up
Golden has been acquired by ComplyAdvantage.Read about it here ⟶
‌

US Patent 10696723 Activatable interleukin 12 polypeptides

Patent 10696723 was granted and assigned to Werewolf Therapeutics on June, 2020 by the United States Patent and Trademark Office.

OverviewStructured DataIssuesContributorsActivity
Is a
Patent
Patent
Current Assignee
Werewolf Therapeutics
Werewolf Therapeutics
Date Filed
June 11, 2019
Date of Patent
June 30, 2020
Patent Applicant
Werewolf Therapeutics
Werewolf Therapeutics
Patent Application Number
16438166
Patent Citations
‌
US Patent 10179817 Anti-CD71 antibodies, activatable anti-CD71 antibodies, and methods of use thereof
‌
US Patent 10261083 Compositions and methods for detecting protease activity in biological systems
‌
US Patent 10233244 Anti-ITGA3 antibodies, activatable anti-ITGA3 antibodies, and methods of use thereof
‌
US Patent 10301380 Anti-jagged 1/jagged 2 cross-reactive antibodies, activatable anti-jagged antibodies and methods of use thereof
‌
US Patent 10059762 Anti-EGFR activatable antibodies
‌
US Patent 10077300 Activatable binding polypeptides and methods of identification and use thereof
‌
US Patent 10100106 Single domain serum albumin binding protein
‌
US Patent 10138272 Matriptase and u-plasminogen activator substrates and other cleavable moieties and methods of use thereof
Patent Citations Received
‌
US Patent 12103954 Heterodimeric Fc cytokines and uses thereof
0
‌
US Patent 11883432 Chimeric antigen receptor system with adaptable receptor specificity
0
‌
US Patent 12091442 Activatable cytokine constructs and related compositions and methods
0
‌
US Patent 11471490 T cells surface-loaded with immunostimulatory fusion molecules and uses thereof
‌
US Patent 11661459 Artificial cell death polypeptide for chimeric antigen receptor and uses thereof
0
‌
US Patent 11667687 Masked activatable interferon constructs
0
‌
US Patent 11365233 Activatable cytokine constructs and related compositions and methods
Patent Jurisdiction
United States Patent and Trademark Office
United States Patent and Trademark Office
Patent Number
10696723
Patent Primary Examiner
‌
Prema M Mertz

Find more entities like US Patent 10696723 Activatable interleukin 12 polypeptides

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
Open Query Tool
Access by API
Golden Query Tool
Golden logo